Eli Lilly’s Alzheimer’s Drug Slows Progression of Disease By One Third in Trial
Good news! Eli Lilly’s experimental Alzheimer’s drug, donanemab, has shown effectiveness in slowing the progression of the disease by one third in a recent trial on early stage patients. Alzheimer’s is targeted by donanemab, an antibody drug, by attacking clumps of the protein beta amyloid from the patient’s brain. This Alzheimer’s related protein forms plaques in the brains of those affected by the disease. The drug targets a specific beta amyloid known as N3pG, which Lilly feels can be cleared quickly and sustainably.
The study was a small trial and needs to be repeated in a larger class, and 27% of the participants did have a side effect known as ARIA-E or brain swelling, but this is a promising approach that can hopefully be an effective treatment.